Predict your next investment

Non-Profit Foundation
acgtfoundation.org

See what CB Insights has to offer

Investments

1

About Alliance for Cancer Gene Therapy

The Alliance for Cancer Gene Therapy is a public charity dedicated exclusively to investing in research into cancer gene therapies. ACGT is committed to building alliances between philanthropic individuals and organizations, and medical and academic institutions, to promote gene therapy research to combat cancer.

Alliance for Cancer Gene Therapy Headquarters Location

Ninety Six Cummings Point Road

Stamford, Connecticut, 06902,

United States

203.358.8000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Alliance for Cancer Gene Therapy

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Alliance for Cancer Gene Therapy in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Latest Alliance for Cancer Gene Therapy News

St. Jude's researchers receive ACGT Grant to tackle challenges of pediatric sarcomas

Feb 9, 2020

An innovative approach to tackling the challenges of pediatric sarcomas is being pursued by researchers at St. Jude Children's Research Hospital (Memphis, Tennessee) with a new grant from Alliance for Cancer Gene Therapy (ACGT). The $500,000 ACGT grant supports Stephen Gottschalk, MD, chair of Bone Marrow Transplantation and Cellular Therapy at St. Jude's, in exploring the use of genetically engineered immune cells to attack pediatric sarcoma. Dr. Gottschalk and his team target not only the cancer, but the blood vessels supporting tumor growth. Dr. Gottschalk has conducted more than 25 previous clinical trials and most recently worked on gene therapies for treating infants with the "bubble boy" disease. There is an urgent need to develop meaningful treatments for children with solid tumors. Dr. Gottschalk's research combines state-of-the-art technologies and methodologies to attack two targeted gene proteins found in pediatric sarcomas. The members of the ACGT Scientific Advisory Council are enthusiastic about Dr. Gottschalk's vision and very promising preliminary data." Kevin Honeycutt, CEO and president of ACGT Related Stories "Pediatric sarcoma, which comes back after initial therapy or is present at multiple sites, is difficult to treat even with the most aggressive, currently available therapies," noted Dr. Gottschalk. "Because Sarcomas are a relatively uncommon group of cancers, accounting for about 15 percent of childhood cancers, improving outcomes has been challenging. This ACGT grant enables me to further investigate how we can leverage different proteins to attack not only abnormal sarcoma cells but also the blood vessels that provide nutrients to tumors. We've seen this approach work in mice. Given the resources from ACGT, we can move ahead much faster to complete all the preclinical studies that are needed to evaluate our approach in the clinic." Dr. Savio Woo, chairman emeritus of the ACGT Scientific Advisory Council and recently retired from the Icahn School of Medicine at Mount Sinai (New York, New York), dedicated his career to the pursuit of fundamental science and technology development in gene and cell therapy, and translating those laboratory advances into direct patient benefit. Dr. Gottschalk, who did a post-doctoral session with Dr. Woo from 1992 to 1995, acknowledges that it was Dr. Woo's commitment to ACGT that drove his quest to secure a grant from the organization. "Being connected to the organization that Dr. Savio Woo helped direct on the scientific side, is a great honor," said Dr. Gottschalk. Source:

Alliance for Cancer Gene Therapy Investments

1 Investments

Alliance for Cancer Gene Therapy has made 1 investments. Their latest investment was in Viridos as part of their Series B on June 6, 2007.

CBI Logo

Alliance for Cancer Gene Therapy Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/8/2007

Series B

Viridos

Yes

Date

6/8/2007

Round

Series B

Company

Viridos

Amount

New?

Yes

Co-Investors

Sources

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.